A diagnosis alone does not automatically entitle someone to a cannabis prescription in the UK. When people ask, “what conditions qualify for medical cannabis?”, the more accurate answer is that a specialist prescriber assesses the person, their symptoms, previous treatment and the balance of likely benefit against risk.
Medical cannabis has been legal to prescribe in the UK since November 2018, but access remains tightly controlled. Most prescriptions are issued through private clinics, while NHS prescribing is limited to a small number of licensed cannabis-based medicines and specialist circumstances. This is not a walk-in route to cannabis, nor is it the same as buying CBD products from a high-street shop.
What conditions qualify for medical cannabis in the UK?
There is no official, fixed UK list of qualifying conditions for unlicensed cannabis-based medicinal products. A clinician can prescribe one where they consider it clinically appropriate, but they must take professional responsibility for that decision. In practice, private medical cannabis clinics commonly assess adults with chronic symptoms that have not responded adequately to conventional treatment.
Chronic pain is among the most common reasons for an assessment. This can include neuropathic pain, fibromyalgia, arthritis-related pain, migraine, pain linked to injury, and persistent pain following surgery. A patient may have a recognised diagnosis, but the key issue is usually whether their symptoms remain difficult to manage despite appropriate treatment.
Neurological conditions are also frequently considered. People with multiple sclerosis may seek treatment for pain, sleep problems or muscle spasticity. Parkinson’s disease, Tourette syndrome and other neurological disorders may also be discussed by specialist clinics, although the evidence and prescribing approach differ substantially between conditions.
Some private services assess patients with psychiatric conditions, including anxiety disorders, post-traumatic stress disorder, insomnia and, less commonly, depression. This is an area where caution matters. Cannabis can worsen anxiety for some people, and THC-containing medicines may be unsuitable for those with a personal or close family history of psychosis, schizophrenia or bipolar disorder. A responsible prescriber should explore mental health history in detail rather than treating anxiety as an automatic indication.
Other conditions that may be considered include inflammatory bowel disease, endometriosis, chronic fatigue symptoms, cancer-related symptoms and palliative care needs. Eligibility varies between clinics, and a condition being mentioned on a clinic website is not a guarantee of a prescription.
The established NHS medicines are more narrowly defined
The position is clearer for medicines licensed for specific uses. Sativex, which contains THC and CBD, can be prescribed for moderate to severe spasticity in multiple sclerosis when other treatments have not worked. Epidyolex, a purified CBD medicine, is used for particular severe childhood-onset epilepsies under specialist care. Nabilone, a synthetic cannabinoid, may be prescribed for chemotherapy-induced nausea and vomiting when other anti-sickness medicines are insufficient.
These are regulated medicines with defined indications. They should not be confused with the broader range of unlicensed cannabis-based products prescribed by some private doctors.
Diagnosis matters, but treatment history often matters more
For many private medical cannabis assessments, the central question is not simply “Do you have this condition?” It is whether standard options have been tried, tolerated and found ineffective or unsuitable.
Clinics commonly ask for a summary of care records from a GP or consultant. These records can help confirm a diagnosis, show previous medicines, and identify relevant safety concerns. Patients are often expected to have tried two conventional treatments for their condition, although this is a common clinic threshold rather than a law written into medical cannabis legislation.
What counts as a previous treatment depends on the condition. For chronic pain, it could include physiotherapy, anti-inflammatory medicines, antidepressants used for neuropathic pain, anticonvulsants, injections or pain-management programmes. For anxiety, it might include talking therapies and appropriate prescribed medicines. A patient does not necessarily need to exhaust every possible option, particularly if a treatment caused serious side effects or is clinically inappropriate.
A good consultation should also consider symptom severity, daily functioning, work and sleep, current medicines, substance-use history and the patient’s goals. Reducing pain from eight out of ten to six may still be clinically meaningful if it allows someone to sleep or move more easily. Equally, a prescription is harder to justify if the likely benefits are vague and the risks are significant.
Why private clinics may reach different decisions
Two clinics can review similar records and make different decisions. That can be frustrating, but it reflects the fact that unlicensed prescribing relies on clinical judgement and each service may have its own governance rules.
Some clinics will not assess patients with certain cardiovascular conditions, unmanaged mental illness, pregnancy or breastfeeding, or a history of psychosis. Others may require a stable mental health plan, a consultant letter or additional screening before proceeding. Age limits also vary, though private prescribing is generally focused on adults.
The type of product may affect the decision. CBD-dominant preparations may be considered differently from THC-containing oils or flower products. Prescribed cannabis flower is usually intended for vapourisation, not smoking. A clinician may start at a low dose, favour an oil over flower, or avoid THC altogether depending on the patient’s symptoms and risk profile.
Cost can also shape real-world access. Private consultations, repeat appointments and medicines are normally paid for by the patient. The fact that a doctor thinks a trial is reasonable does not mean it will be affordable over time.
What evidence supports medical cannabis?
The evidence is strongest for a limited group of licensed medicines and specific indications. For many symptoms commonly seen at private clinics, especially chronic pain, sleep disturbance and anxiety, evidence is mixed, condition-specific and often based on studies using products that differ from those available on prescription in Britain.
That does not mean patients’ reported benefits are irrelevant. It does mean claims should be measured. A treatment may help one person reduce symptoms or reliance on another medicine, while offering little benefit to another. Side effects can include tiredness, dizziness, dry mouth, impaired concentration, palpitations and anxiety. THC can cause intoxication and, at higher doses or in susceptible people, paranoia or more serious psychiatric effects.
The medical rationale should therefore be a monitored trial, not a promise. Follow-up appointments are used to review symptom change, side effects, dose and whether continuing treatment remains justified. Patients should tell their prescriber about adverse effects, alcohol use and any changes to their other medicines.
Legal and practical points patients should not overlook
A valid private prescription does not create a general exemption from cannabis laws. It permits the named patient to possess and use the prescribed medicine as directed, but sharing it, selling it or using it outside those directions remains unlawful.
Driving is a separate issue. Some prescribed cannabis medicines contain THC, which is covered by UK drug-driving limits. A patient may have a medical defence if the medicine was prescribed and taken as directed, but that defence does not apply if they are impaired. The practical rule is straightforward: do not drive if you feel sleepy, slowed, dizzy, intoxicated or otherwise unfit to drive. Police can still stop a driver, conduct a roadside test and investigate.
Patients should keep medicine in its original labelled packaging and carry a copy of their prescription or clinic letter when travelling within the UK. Taking prescribed cannabis abroad requires separate checks with the destination country and carrier. A UK prescription does not override another country’s drug laws.
Finally, retail CBD is not medical cannabis. A CBD oil sold as a food supplement is not an alternative to a prescribed cannabis-based medicine, and its quality, cannabinoid content and legal status are assessed differently.
Questions worth asking before an assessment
Before paying for an appointment, ask whether the clinic treats your condition, what records it needs, its policy on prior treatments and the likely first-year cost. It is also reasonable to ask which clinician will assess you, how follow-up works, and what happens if treatment is ineffective or causes side effects.
The most useful starting point is a clear record of your symptoms and treatment history, not a search for a diagnosis that supposedly guarantees access. Medical cannabis prescribing in the UK is case-by-case, and the best clinics will be candid when the evidence, safety profile or expected benefit does not support a prescription.
